Virexx Medical Corporation

Imbiotechnologies Ltd

Virexx Medcial Corp.

Roland Henryk Person

Antoine A Noujaim

Michael William Stewart

Bruce D Hirsche, Legal Representative

Antoine (deceased) Noujaim

Irwin J Griffith

Paul B Tiege

The present invention relates generally to methods and compositions for treating a disease or condition by administering a first therapeutic protocol comprising targeting and delivering solid-phase platelet-dependent vascular occlusion agents, and administering at least one second therapeutic composition or method.

Methods of treatment using vascular occlusion in combination therapies

The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the formation of a platelet-mediated thrombus-causing vessel occlusion.

Compositions and methods for producing vascular occlusion

The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.

Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent

Growing community of inventors

Edmonton, Canada

Roland Henryk Person